Regulus Therapeutics Inc. (NASDAQ:RGLS) has earned an average recommendation of “Hold” from the nine brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and one has given a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $3.00.
A number of equities analysts recently commented on RGLS shares. Zacks Investment Research raised shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price target on the stock in a research report on Wednesday, July 12th. BMO Capital Markets set a $1.00 price target on shares of Regulus Therapeutics and gave the stock a “hold” rating in a research report on Monday, June 12th. ValuEngine lowered shares of Regulus Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Chardan Capital lowered shares of Regulus Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, August 2nd. Finally, Wedbush reissued an “ourperform” rating and issued a $6.00 target price on shares of Regulus Therapeutics in a report on Tuesday, June 13th.
In related news, insider Joseph P. Hagan purchased 219,780 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The shares were bought at an average cost of $0.91 per share, with a total value of $199,999.80. Following the acquisition, the insider now owns 241,297 shares of the company’s stock, valued at approximately $219,580.27. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Daniel R. Chevallard purchased 54,945 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The shares were bought at an average cost of $0.91 per share, for a total transaction of $49,999.95. Following the completion of the acquisition, the chief financial officer now directly owns 59,415 shares in the company, valued at approximately $54,067.65. The disclosure for this purchase can be found here. Insiders have purchased a total of 549,450 shares of company stock worth $500,000 over the last ninety days. 4.80% of the stock is currently owned by insiders.
Large investors have recently bought and sold shares of the company. FMR LLC increased its stake in Regulus Therapeutics by 0.5% in the second quarter. FMR LLC now owns 7,977,349 shares of the biopharmaceutical company’s stock valued at $7,862,000 after buying an additional 37,489 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in Regulus Therapeutics during the second quarter valued at approximately $139,000. Quantitative Investment Management LLC acquired a new stake in Regulus Therapeutics during the second quarter valued at approximately $103,000. LMR Partners LLP acquired a new stake in Regulus Therapeutics during the second quarter valued at approximately $164,000. Finally, Wedbush Securities Inc. increased its stake in Regulus Therapeutics by 10.3% in the second quarter. Wedbush Securities Inc. now owns 199,521 shares of the biopharmaceutical company’s stock valued at $197,000 after buying an additional 18,600 shares in the last quarter. Institutional investors and hedge funds own 21.09% of the company’s stock.
Shares of Regulus Therapeutics (NASDAQ:RGLS) opened at 0.9201 on Friday. The company has a 50-day moving average price of $0.99 and a 200 day moving average price of $1.29. Regulus Therapeutics has a one year low of $0.85 and a one year high of $3.68. The firm’s market capitalization is $95.49 million.
Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by $0.10. Regulus Therapeutics had a negative return on equity of 173.20% and a negative net margin of 31,460.47%. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. Analysts expect that Regulus Therapeutics will post ($1.10) earnings per share for the current fiscal year.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
What are top analysts saying about Regulus Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regulus Therapeutics Inc. and related companies.